JAK/STAT Inhibition May Be Promising in AF10-Rearranged Leukemia
Researchers sought to determine whether JAK1 inhibition would be a therapeutic target in patients with AF10-rearranged acute myeloid leukemia.
Acute Myeloid Leukemia
Gemtuzumab Ozogamicin Can Improve Outcomes in Pediatric KMT2A-Rearranged Acute Myeloid Leukemia
Gemtuzumab ozogamicin improved event-free survival and disease-free survival.
Gene Mutations in IDH-Mutated Acute Myeloid Leukemia Have Prognostic Significance
Researchers sought to determine what genetic mutations may have prognostic significance for chemotherapy and stem cell transplant in patients with AML.
Lower Mutation Burden With Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Patients With Myelodysplastic Syndromes
Researchers sought to determine whether pevonedistat plus azacitidine would result in a lower residual mutation load than seen with azacitidine alone in patients with MDS.
Integrated Palliative Care Improves Symptoms, Coping in Patients Hospitalized for Acute Myeloid Leukemia Treatment
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Leukemia-Specific T-cells Promising for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Researchers sought to determine whether leukemia-specific T-cells would be a safe treatment for patients with AML or MDS after HSCT.
Relapsed/Refractory, IDH2-Mutated AML: Olutasidenib Shows Promise
IDH1 differentiation syndrome of any grade was noted in 14% of patients, with 1 fatal case.
At-Home Chemotherapy Appears Safe, Feasible for Acute Myeloid Leukemia, Myelodysplastic Syndromes
Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.
New Prognostic Model for Patients With Acute Myeloid Leukemia With High-Risk Mutations
Researchers sought to identify a new model for predicting survival in patients with with acute myeloid leukemia.
Patients With Acute Myeloid Leukemia May Have Suboptimal Outcomes Because of Fears of Treatment Side Effects
Researchers sought to determine whether patients with AML were being undertreated due to patient fear about side effects to treatment.
- Loading...
Loading...
Loading... 
Loading...